Kubota Pharmaceutical Holdings Co. Ltd. · TSE:4596

Kubota Pharmaceutical — FY2016 Earnings Presentation

44 slides from Kubota Pharmaceutical's earnings presentation, Feb 21, 2017

  1. Slide 1: Kubota Pharmaceutical Holdings FY2016 Analyst Meeting

    Kubota Pharmaceutical Holdings is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical Holdings FY2016 Analyst Meeting Tokyo February 22, 2017

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    Cautionary Statement Regarding Forward Looking Statements 2 This presentation contains forward-looking statements concerning our product development, our ability to successfully commercialize our product candidates, our technology, our competitors, our intellectual property, our financial condition

  3. Slide 3: Company Overview: An Ophthalmology-Focused, Science-Driven Company

    Company Overview An Ophthalmology-Focused, Science-Driven Company 3 Partnership • Partnership with YouHealth and University of California, San Diego to address cataracts and presbyopia with lanosterol • Partnership with The University of Manchester to address retinal degenerative disease with gene t

  4. Slide 4: Leading Causes of Blindness Worldwide

    Cataract 51% Glaucoma 8% AMD 5% Corneal Opacities 4% Childhood Blindness 4% Refractive Error 3% Trachoma 3% Diabetic Retinopathy 1% Undetermined 21% Leading Causes of Blindness Worldwide 4 • 33 million people blind worldwide • 191 million suffer from moderate and severe vision impairment (MSVI) Sour

  5. Slide 5: Leading Causes of Blindness in Japan, US and Europe

    Leading Causes of Blindness in Japan, US and Europe 5 Glaucom a 21% 16% 8% 34% 10% Source: 1) 厚生労働省 難治性疾患等克服研究事業「網膜脈絡膜・視神経萎縮症に関する調査研究 平成25(2013)年度」報告書 (A 2013 Report by Ministry of Health, Labour and Welfare) 2) Nathan C. et al. Causes and Prevalence of Visual Impairment Among Adults in the United S

  6. Slide 6: Retinal Diseases Market Forecast: Global Market

    Global revenue forecast to reach $17.5B in 2020 CAGR 6.7% from 2017 – 2020 6 Sources: Visiongain, Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025。 Market Scope, 2015 Comprehensive Report on the Global IOL Market。 Retinal Diseases Market Forecast: Globa

  7. Slide 7: Bridging the Investment Chasm in Development

    Discovery Exploratory Confirmatory Forge Partnerships In House In House / Partnered Business Development Opportunity 7 • We believe an investment chasm exists for exploratory projects in the U.S. Kubota Pharma’s opportunity is to bridge the chasm between early and late stage development: − Partner w

  8. Slide 8: Project Portfolio

    Project Portfolio 8 Technology Therapeutic Area Pre- clinical Phase 1 Phase 2 Phase 3 POC Target*1 Origin VCM*2 Emixustat HCI Proliferative Diabetic Retinopathy (PDR) 2017 Proprietary Stargardt disease 2018 Proprietary Intermediate AMD 2019 Proprietary Lanosterol Cataract, Presbyopia 2018 University

  9. Slide 9: Emixustat Hydrochloride for Diabetic Retinopathy

    Emixustat Hydrochloride for Diabetic Retinopathy

  10. Slide 10: Manifestations and Treatment of Diabetic Retinopathy

    Generally no treatment Anti-VEGF, Corticosteroids, Vitrectomy Manifestations and Treatment of Diabetic Retinopathy 10 Diabetic macular edema Hard exudates in fovea Cotton wool spots Neovascularization Proliferative DR New vessels surrounded by hard exudate Nonproliferative DR Retinal hemorrhages Kub

  11. Slide 11: Emixustat: a Potential Paradigm Shift in Treatment of Diabetic Retinopathy

    Emixustat: a Potential Paradigm Shift in the Treatment of Diabetic Retinopathy 11 Mimic constitutive phototransduction Reduction in neovascularization Oral administration Potential to transform current therapeutic landscape of invasive treatment modalities To benefit more patients • Initial focus on

  12. Slide 12: Phase 2 Study of Emixustat in PDR is Underway

    Phase 2 Study of Emixustat in Proliferative Diabetic Retinopathy (PDR) is Underway 12 • Multicenter (up to 6 clinical sites in the US)randomized, double-blinded, placebo- controlled • Up to 20 patients diagnosed with PDR will take emixustat (up to 40 mg, step up titration) or placebo once daily for

  13. Slide 13: Forecast for the Global Diabetic Retinopathy Market

    Forecast for the Global Diabetic Retinopathy(1) Market 13 Kubota Pharmaceutical Holdings Co., Ltd. [4596] 1,716 1,986 2,246 2,492 2017 2018 2019 2020 Source: Visiongain, Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025。 1) Including Proliferative diabet

  14. Slide 14: Emixustat Hydrochloride for Stargardt Disease

    Emixustat Hydrochloride for Stargardt Disease

  15. Slide 15: Stargardt Disease: a Genetic Disorder

    Stargardt Disease: a Genetic Disorder Stargardt disease is a genetically inherited disorder of the retina 15 • Stargardt is a serious unmet medical need, with fewer than 150,000 people estimated to be patients in the US, Japan and Europe, combined. • There are many symptoms a person with Stargardt m

  16. Slide 16: Stargardt Disease Progression and Emixustat Mechanism of Action

    Stargardt Disease: Proposed Disease Progression and Emixustat Mechanism of Action 16 Photoreceptor Cell Death Death of RPE RPE Dysfunction Accumulation of lipofuscin (lipid, proteins, vitamin A toxins) leading to free radical production and activation of complement system Defective gene: ABCA4 Block

  17. Slide 17: Phase 2a Study of Emixustat in Stargardt Disease is Underway

    Phase 2a Study of Emixustat in Stargardt Disease is Underway 17 • Multicenter (up to 6 clinical sites in the US), randomized, double -blinded • Up to 30 patients diagnosed with macular atrophy secondary to Stargardt will be randomly assigned to one of three treatment arms in a 1:1:1 ratio. Treatment

  18. Slide 18: Lanosterol for Cataracts and Presbyopia

    Lanosterol for Cataracts and Presbyopia

  19. Slide 19: Protein Aggregation in Crystalline Lens Leads to Cataract

    Protein Aggregation in Crystalline Lens of the Eye Leads to Cataract 19 Clear Vision Highly ordered proteins Impact on Vision Cloudy Vision Denatured proteins Low protein order / protein aggregation Denatured proteins aggregate and obstruct light, causing cloudy vision Kubota Pharmaceutical Holdings

  20. Slide 20: Lanosterol: New Treatment Potential

    Lanosterol: New Treatment Potential 20 Kubota Pharmaceutical Holdings Co., Ltd. [4596] Currently, there is no non-surgical treatment available for cataracts 1. Multiple incisions are made to access the lens 2. High-frequency ultrasound breaks up the lens into small pieces, then removed with suction

  21. Slide 21: Lanosterol Development Plan

    Lanosterol Development Plan 21 Pre-clinical development necessary to file an IND Phase 1/2 clinical study planned for patients with cataract 2016-2017 2017-2018 Kubota Pharmaceutical Holdings Co., Ltd. [4596] Assess lens opacity in humans, Evaluation of near vision Formulation development Targeted f

  22. Slide 22: Forecast for the Global IOL Market

    Forecast for the Global IOL Market 22 Kubota Pharmaceutical Holdings Co., Ltd. [4596] 3,651 3,864 4,092 4,358 2017 2018 2019 2020 Source: Market Scope, 2015 Comprehensive Report on the Global IOL Market CAGR 6.1% (US$ in millions)

  23. Slide 23: Optogenetics for Retinitis Pigmentosa

    Optogenetics for Retinitis Pigmentosa

  24. Slide 24: Retinitis Pigmentosa is a Blinding Disease

    Retinitis Pigmentosa is a Blinding Disease 24 • Affects roughly 1 in 4,000 people, both in the United States and worldwide (NEI)1 • Approximately 1.5 million people worldwide are affected by the disease2 • Earliest and most frequent symptom is night blindness, decreased vision or tunnel vision 3 • P

  25. Slide 25: Optogenetics: The Technology

    Optogenetics The Technology Technology allows expression of human rhodopsin in ON bipolar cells using a viral vector • Rhodopsin’s biological mechanism imparts a relatively high level of light sensitivity for this type of therapy and as a human protein, may minimize any immunological impact • Geneti

  26. Slide 26: Optogenetics Development Plan

    Optogenetics Development Plan 26 Pre-clinical development necessary to file an IND Anticipated initiation of Phase 2 clinical study 2016-2018 2018-2019 Kubota Pharmaceutical Holdings Co., Ltd. [4596] Kubota Pharma intends to pursue Orphan Drug status to allow for potentially rapid development and ex

  27. Slide 27: ACU-6151 Biomimetic Technology

    ACU-6151 Biomimetic Technology

  28. Slide 28: Retinal Vascular Abnormalities are a Core Pathology in Multiple Eye Diseases

    Retinal Vascular Abnormalities are a Core Pathology in Multiple Sight-threatening Ocular Diseases 28 Kubota Pharmaceutical Holdings Co., Ltd. [4596] Reduced visual acuity Loss of vision Potentially irreversible blindness  Vascular leakage  Proliferation of new abnormal blood vessels at back of eye

  29. Slide 29: Biomimetic Technology

    Biomimetic Technology Potential small molecule pharmacologic treatment for retinal neovascular disease 29 • The proprietary technology modulates endogenous factors released during the inflammatory process at the early pathogenic stages of diabetic macular edema (DME), age-related macular degeneratio

  30. Slide 30: Biomimetic Technology Development Plan

    Biomimetic Technology Development Plan 30 Pre-clinical development necessary to file an IND Anticipated initiation of Phase 2 clinical study 2018 2019-2020 Kubota Pharmaceutical Holdings Co., Ltd. [4596] Targeted for diabetic macular edema (DME), wet AMD, GA associated with dry AMD POC (Proof of Con

  31. Slide 31: Forecast for the Global Wet AMD Market

    Source: Visiongain, Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 Forecast for the Global Wet AMD Market 31 Kubota Pharmaceutical Holdings Co., Ltd. [4596] 6,220 6,424 6,676 6,767 2017 2018 2019 2020 CAGR 2.9% (US$ in millions)

  32. Slide 32: PBOS Patient Based Ophthalmology Suite

    PBOS Patient Based Ophthalmology Suite

  33. Slide 33: PBOS: At-home Patient Self-use Retinal Monitoring Device

    PBOS Patient Based Ophthalmology Suite At home, patient self-use retinal monitoring device 33 • Increase in demand for mobile Health applications (mHealth) in home care and remote medical care field • In its first iteration, the PBOS aims to improve treatment outcome in patients diagnosed and treate

  34. Slide 34: PBOS Development Plan

    PBOS:Micromini Handheld Device Equipped with Optical Coherence Tomography Development Plan 34 Invention and prototyping Anticipated initiation of pre-clinical and clinical studies 2017-2018 2019 Kubota Pharmaceutical Holdings Co., Ltd. [4596] Targeted for wet AMD, DME, and other neovascular retinal

  35. Slide 35: FY2016 Financial Results

    Kubota “SS FY2016 Financial Results

  36. Slide 36: Overview of FY2016: P/L

    Overview of FY2016: P/L JPY in thousands December 31, 2015 December 31, 2016 Reasons for change Revenues from collaboration 2,902,721 870,198 The decrease in revenue from collaborations was primarily due to billing fewer full-time employees as a result of the completion of the Emixustat clinical tri

  37. Slide 37: Overview of FY2016: Balance Sheet

    Overview of FY2016: Balance Sheet 37 JPY in thousands December 31, 2015 December 31, 2016 Reasons for change Current Assets 14,497,458 14,831,434 Cash, cash equivalents and short-term investments 13,509,540 14,248,398 Other current assets 987,918 583,036 Primarily due to decrease in accounts receiva

  38. Slide 38: Financial Outlook

    Financial Outlook* 38 • Outlook for Revenue from collaborations − The Company is pursuing various partnering efforts and is expecting to generate revenue in the future through collaborations with strategic partners. • Outlook for loss from operations − Total research and development expenses are exp

  39. Slide 39: Financial Overview

    848 844 (23) (3,203) (4,121) (4,290) (6,000) (4,000) (2,000) 0 2,000 FY12 FY13 FY14 FY15 FY16 FY17 Est. Operating Profit (Loss) Financial Overview* 39 5,672 6,519 23,756 21,221 17,169 0 5,000 10,000 15,000 20,000 25,000 FY12 FY13 FY14 FY15 FY16 Total Assets 3,088 3,754 22,236 20,074 16,520 0 5,000 1

  40. Slide 40: Appendix

    Kubota “SS Appendix

  41. Slide 41: Management Team

    Management Team Globally experienced management team in the ophthalmology industry 41 Lukas Scheibler, PhD EVP R&D, Acucela Inc. Alcon Novartis Pharmaceuticals John Gebhart Chief Financial Officer Qliance Medical Management Consultant to Remote Medical International, Ventripoint, and others Ted Dans

  42. Slide 42: Board of Directors

    Board of Directors 42 Directors Background Ryo Kubota, MD PhD Chairman, President and Chief Executive Officer and also founder of Acucela Inc. Shintaro Asako Chief Executive Officer and Chief Financial Officer — DeNA Corp Previously: Chief Financial Officer — MediciNova, Inc. Shiro Mita, PhD Preside

  43. Slide 43: Recent Events

    Recent Events 43 Date Highlights Mar 17 ‘16 Acucela Secures Option to Exclusively License Novel Cataract Treatment April 5 ‘16 Acucela Licenses Gene Therapy from The University of Manchester for Retinal Degenerative Disease May 25 ’16 Announcement of Top-Line Results from Phase 2b/3 Clinical Trial o

  44. Slide 44: Kubota Pharmaceutical Holdings is committed to translating innovation into a diverse portfolio of drugs

    Kubota Pharmaceutical Holdings is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.

Kubota Pharmaceutical Holdings — FY2016 Earnings Presentation on 6ix